Collectively, this study not only establishes LYZ as a novel biomarker for age-related vascular diseases and the gut microbiota–PI3K–Akt axis as a promising therapeutic target but also propels translational research forward, highlighting the potential of gut-targeted strategies for mitigating vascular inflammatory aging (Fig. 9). The gene discussed is LYZ; the disease is age.